- Home
- SNN vs NBIX Comparison
SNN vs NBIX Comparison
Compare SNN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNN | NBIX |
|---|---|---|
| Founded | 1856 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 14.4B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SNN | NBIX |
|---|---|---|
| Price | $33.44 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $32.83 | ★ $173.79 |
| AVG Volume (30 Days) | 476.9K | ★ 969.9K |
| Earning Date | 03-02-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 59.91 | 12.44 |
| EPS | 0.56 | ★ 4.19 |
| Revenue | ★ $5,944,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $7.78 | $23.76 |
| Revenue Next Year | $5.13 | $18.01 |
| P/E Ratio | ★ $29.10 | $37.10 |
| Revenue Growth | 5.35 | ★ 19.61 |
| 52 Week Low | $23.69 | $84.23 |
| 52 Week High | $38.79 | $157.67 |
Technical Indicators
Market Signals| Indicator | SNN | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 64.81 |
| Support Level | $32.68 | $150.26 |
| Resistance Level | $33.56 | $154.35 |
| Average True Range (ATR) | 0.41 | 4.16 |
| MACD | 0.14 | 1.07 |
| Stochastic Oscillator | 78.51 | 93.25 |
Price Performance
Historical ComparisonAbout SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.